Urticaria control test might misevaluate disease control in particular patients treated with omalizumab

Since its effectiveness in H1-antihistamine refractory chronic spontaneous urticaria (CSU) was shown, omalizumab has been increasingly used across the world. Omalizumab is licensed at a dose of 300 mg subcutaneously every 4 weeks in Turkey and in the European Union[1, 2]. The urticaria activity, control and response to treatment should be assessed by a reliable and easily applicable tool during this 4 week-interval. Urticaria activity score (UAS) and urticaria control test (UCT) are two well-developed and validated patient reported outcome measures (PRO).

https://ift.tt/2G0JApq